1. Aas T, Børresen A-L, Geisler S, Smith-Sørensen B, Johnsen H, Varhaug JE, Akslen LA, Lønning PE (1996) Specific p53 mutations are associated withde novo resistance to doxorubicin in breast cancer patients. Nat Med 2: 811
2. Abarzúa P, LoSardo JE, Gubler ML, Neri A (1995) Microinjection of monoclonal antibody PAb421 into human SW480 colorectal carcinoma cells restores the transcription activation function to mutant p53. Cancer Res 55: 3490
3. Adams PD, Kaelin WG Jr (1996) The cellular effects of E2F overexpression. Curr Top Microbiol Immunol 208: 79
4. Arrowsmith CH, Morin P (1996) New insights into p53 function from structural studies. Oncogene 12: 1379
5. Attardi LD, Lowe SW, Brugarolas J, Jacks T (1996) Transcriptional activation by p53, but not induction of the p21 gene, is essential for oncogene-mediated apoptosis. EMBO J 15: 3693